News & Press Releases Swedish

Scandinavian ChemoTech AB lanserar sin profil på The Ecoptimist

Som ett led i att öka vår närvaro på internet har vi nu lanserat vår bolagsprofil på The Ecoptimist hemsida. www.Ecoptimist.se (http://www.TheEcoptimist.se) publicerar aktiespaningar, trendspaningar och generella tankar kring börsen. De tittar främst på mindre tillväxtbolag men ibland även större bolag och potentiella turnaroundcase. För den som vill lära sig mer om aktieanalys har de även…

Read more

Scandinavian ChemoTech lägger 2020 bakom sig och blickar framåt

2020 var ett år som fick en god start med ökat antal behandlingar och nya avtal för ChemoTech, detta trots den stora förändring som pandemin haft på världsekonomin och på vår möjlighet att marknadsföra oss.

Read more

Scandinavian ChemoTech AB meddelar inlösen av teckningsoptioner av serie TO1 och TO2 registrerat vid Bolagsverket

Bolagsverket har nu registrerat ökning av aktier och aktiekapital i Scandinavian ChemoTech AB (publ) (”ChemoTech” eller ”Bolaget”) hänförligt till utnyttjandet av teckningsoptioner av serie TO1 och TO2 (”Teckningsoptionerna”).

Read more

News & Press Releases English

Scandinavian ChemoTech receives a final injunction from the European Patent Office

Scandinavian ChemoTech AB announces today that the Company has received a final injunction from the European Patent Office where the examiner announces that the patent for the Company's innovation, for TSE treatment of skeletal metastases and deep-seated tumours, will be granted.

Read more

Scandinavian ChemoTech enters into an agreement with Erik Penser Bank to monitor the company in the form of assignment analyses

Scandinavian ChemoTech AB (publ) has entered into an agreement with Erik Penser Bank AB to receive the service, Penser Access, where written analysis reports are the central part of the service.

Read more

Scandinavian ChemoTech AB receives final injunction on EU patent for its technology platform for dynamic electroporation

ChemoTech has received a 71(3), also called final injunction, from the European Patent Office, which announces that one of the company's European patent applications will be approved.

Read more

Chemotech Videos

Erik Penser Bank interview with CEO Mohan Frick (Swedish)

Company Presentation of the Q3 report (Swedish) 11th of November 2020

Company Presentation (Swedish) 27th of October 2020

Share Day in Gothenburg, November 4 2019

Share Day in Malmö on May 22, 2018

Share analysis ChemoTech Q2 2018

Our foundation

Our profound knowledge in Electroporation forms the starting point for the company’s existing product and R&D projects : IQwave™ specially desinged for both Dynamic-ElectroEnhanced Chemotherapy and the first generation Electrochemotherpy for the treatment of a range of different types of tumors.

Our research focus

Our aim is to document the effects of elctrochemotherapy for pain management for cancer patients, an area with significant unmet medical need.